Vertex Pharmaceuticals (VRTX) Long-Term Investments (2016 - 2026)

Vertex Pharmaceuticals has reported Long-Term Investments for 7 years, with the latest figure at $5.8 billion in Q2 2026.

• On a quarterly basis, Long-Term Investments rose 2.54% year-over-year to $5.8 billion in Q2 2026; TTM through Jun 2026 was $5.8 billion, a 2.54% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 11.83% from the prior year.
• Long-Term Investments was $5.8 billion for Q2 2026 at Vertex Pharmaceuticals, up from $5.7 billion in the prior quarter.
• The five-year high for Long-Term Investments was $5.8 billion in Q2 2026, with the low at $112.2 million in Q4 2022.
• Average Long-Term Investments over 5 years is $3.9 billion, with a median of $4.7 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Long-Term Investments surged 2126.2% in 2023, then grew 2.54% in 2026.
• Over 5 years, Long-Term Investments stood at $112.2 million in 2022, then soared by 2126.2% to $2.5 billion in 2023, then jumped by 104.5% to $5.1 billion in 2024, then gained by 11.83% to $5.7 billion in 2025, then rose by 1.34% to $5.8 billion in 2026.
• The last three Long-Term Investments figures came in at $5.8 billion (Q2 2026), $5.7 billion (Q1 2026), and $5.7 billion (Q4 2025), per Business Quant data.